Magnolol restores the activity of meropenem against NDM-1-producing Escherichia coli by inhibiting the activity of metallo-beta-lactamase

Cell Death Discovery

Volumn 4, Issue 1, 2018, Pages

  Liu, Shui ^a   Zhou, Yonglin ^a   Niu, Xiaodi ^a   Wang, Tingting ^a   Li, Jiyun ^b   Liu, Zhongjie ^b   Wang, Jianfeng ^a   Tang, Shusheng ^b   Wang, Yang ^b   Deng, Xuming ^a  

^a JILIN UNIVERSITY   (China)

^b CHINA AGRICULTURAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85054676512     PISSN: None     EISSN: 20587716     Source Type: Journal    
DOI: 10.1038/s41420-018-0029-6     Document Type: Article

References (41)

1. Spellberg, B. et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46, 155–164 (2008).
2. Brown, E. D. & Wright, G. D. Antibacterial drug discovery in the resistance era. Nature 529, 336–343 (2016).
3. Alm, R. A., Johnstone, M. R. & Lahiri, S. D. Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3. J. Antimicrob. Chemother. 70, 1420–1428 (2015).
4. Schneider, K. D., Karpen, M. E., Bonomo, R. A., Leonard, D. A. & Powers, R. A. The 1.4 A crystal structure of the class D beta-lactamase OXA-1 complexed with doripenem. Biochemistry 48, 11840–11847 (2009).
5. Karaiskos, I. & Giamarellou, H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin. Pharmacother. 15, 1351–1370 (2014).
6. Livermore, D. M. Has the era of untreatable infections arrived? J. Antimicrob. Chemother. 64(Suppl 1), i29–i36 (2009).
7. Bush, K. & Jacoby, G. A. Updated functional classification of beta-lactamases. Antimicrob. Agents Chemother. 54, 969–976 (2010).
8. Yong, D. et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents Chemother. 53, 5046–5054 (2009).
9. Berrazeg, M. et al. New Delhi Metallo-beta-lactamase around the world: an eReview using Google Maps. Eur. Surveill. 19, 20 (2014).
10. Kumarasamy, K. K. et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10, 597–602 (2010).
11. Struelens M. J., Monnet D. L., Magiorakos A. P., Santos O’Connor F., Giesecke J. European NDMSP. New Delhi metallo-beta-lactamase 1-producing Enterobacteriaceae: emergence and response in Europe. Eur. Surveill. 15, 9–16 (2010).
12. Nordmann, P., Poirel, L., Walsh, T. R. & Livermore, D. M. The emerging NDM carbapenemases. Trends Microbiol. 19, 588–595 (2011).
13. Cornaglia, G., Giamarellou, H. & Rossolini, G. M. Metallo-beta-lactamases: a last frontier for beta-lactams? Lancet Infect. Dis. 11, 381–393 (2011).
14. Nordmann, P., Poirel, L., Toleman, M. A. & Walsh, T. R. Does broad-spectrum beta-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria? J. Antimicrob. Chemother. 66, 689–692 (2011).
15. Walsh, T. R. Emerging carbapenemases: a global perspective. Int. J. Antimicrob. Agents 36(Suppl 3), S8–S14 (2010).
16. Hsu, L. Y. & Koh, T. H. World Health Day 2011: combating antimicrobial resistance. Singap. Med. J. 52, 230–231 (2011).
17. Ellar, D. J. & Lundgren, D. G. Fine structure of sporulation in Bacillus cereus grown in a chemically defined medium. J. Bacteriol. 92, 1748–1764 (1966).
18. Drawz, S. M. & Bonomo, R. A. Three decades of beta-lactamase inhibitors. Clin. Microbiol. Rev. 23, 160–201 (2010).
19. Albu, S. A. et al. Total synthesis of Aspergillomarasmine A and related compounds: a sulfamidate approach enables exploration of structure-activity relationships. Angew. Chem. 55, 13259–13262 (2016).
20. Liao, D. et al. Total synthesis and structural reassignment of Aspergillomarasmine A. Angew. Chem. 55, 4291–4295 (2016).
21. King, A. M. et al. Aspergillomarasmine A overcomes metallo-beta-lactamase antibiotic resistance. Nature 510, 503–506 (2014).
22. King, D. T., Worrall, L. J., Gruninger, R. & Strynadka, N. C. New Delhi metallo-beta-lactamase: structural insights into beta-lactam recognition and inhibition. J. Am. Chem. Soc. 134, 11362–11365 (2012).
23. Chiou, J. et al. Ebselen as a potent covalent inhibitor of New Delhi metallo-beta-lactamase (NDM-1). Chem. Commun. 51, 9543–9546 (2015).
24. Klingler, F. M. et al. Approved drugs containing thiols as inhibitors of metallo-beta-lactamases: strategy to combat multidrug-resistant bacteria. J. Med. Chem. 58, 3626–3630 (2015).
25. Alexeev, M., Grosenbaugh, D. K., Mott, D. D. & Fisher, J. L. The natural products magnolol and honokiol are positive allosteric modulators of both synaptic and extra-synaptic GABA(A) receptors. Neuropharmacology 62, 2507–2514 (2012).
26. Chen, L. et al. Rapid purification and scale-up of honokiol and magnolol using high-capacity high-speed counter-current chromatography. J. Chromatogr. A 1142, 115–122 (2007).
27. Lee, Y. J. et al. Therapeutic applications of compounds in the Magnolia family. Pharmacol. Ther. 130, 157–176 (2011).
28. Wang, Y. J., Chien, Y. C., Wu, C. H. & Liu, D. M. Magnolol-loaded core-shell hydrogel nanoparticles: drug release, intracellular uptake, and controlled cytotoxicity for the inhibition of migration of vascular smooth muscle cells. Mol. Pharm. 8, 2339–2349 (2011).
29. He, S., Zhang, Z., Xu, F., Zhang, S. & Lei, Z. Micronization of magnolia bark extract with enhanced dissolution behavior by rapid expansion of supercritical solution. Chem. Pharm. Bull. 58, 154–159 (2010).
30. Matsuura, A. et al. Pharmacological profiles of aspergillomarasmines as endothelin converting enzyme inhibitors. Jpn. J. Pharmacol. 63, 187–193 (1993).
31. Li, N. et al. Evaluation of the in vitro and in vivo genotoxicity of magnolia bark extract. Regul. Toxicol. Pharmacol. RTP 49, 154–159 (2007).
32. Liu, Z. et al. Evaluation of short-term and subchronic toxicity of magnolia bark extract in rats. Regul. Toxicol. Pharmacol. RTP 49, 160–171 (2007).
33. Poivre, M. & Duez, P. Biological activity and toxicity of the Chinese herb Magnolia officinalis Rehder & E. Wilson (Houpo) and its constituents. J. Zhejiang Univ. Sci. B 18, 194–214 (2017).
34. Wang, Y. et al. Comprehensive resistome analysis reveals the prevalence of NDM and MCR-1 in Chinese poultry production. Nat. Microbiol. 2, 16260 (2017).
35. Kang, W. et al. Effective antimicrobial activity of a peptide mutant Cbf-14-2 against penicillin-resistant bacteria based on its unnatural amino acids. Eur. J. Pharm. Sci. 105, 169–177 (2017).
36. Morris, G. M. et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 30, 2785–2791 (2009).
37. Hu, R., Barbault, F., Maurel, F., Delamar, M. & Zhang, R. Molecular dynamics simulations of 2-amino-6-arylsulphonylbenzonitriles analogues as HIV inhibitors: interaction modes and binding free energies. Chem. Biol. Drug Des. 76, 518–526 (2010).
38. Dong, J. et al. Oroxylin A inhibits hemolysis via hindering the self-assembly of alpha-hemolysin heptameric transmembrane pore. PLoS Comput. Biol. 9, e1002869 (2013).
39. Niu, X. et al. Molecular insight into the inhibition mechanism of cyrtominetin to alpha-hemolysin by molecular dynamics simulation. Eur. J. Med. Chem. 62, 320–328 (2013).
40. Jurasekova, Z., Marconi, G., Sanchez-Cortes, S. & Torreggiani, A. Spectroscopic and molecular modeling studies on the binding of the flavonoid luteolin and human serum albumin. Biopolymers 91, 917–927 (2009).
41. Bandyopadhyay, S., Valder, C. R., Huynh, H. G., Ren, H. & Allison, W. S. The beta G156C substitution in the F1-ATPase from the thermophilic Bacillus PS3 affects catalytic site cooperativity by destabilizing the closed conformation of the catalytic site. Biochemistry 41, 14421–14429 (2002).